Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Victor Evans

Child & Adolescent Psychiatry Lexington, SC Medical Doctor

NPI 1386703700 CMS profile 153136

305 Palmetto Park Blvd, Lexington, SC 29072

Open in the dashboard

General payments

$25,858

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victor Evans of Lexington, SC is reported in the CMS Open Payments database as having received $25,858 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $579 33
2024 General $436 26
2023 General $2,849 29
2022 General $619 37
2021 General $3,392 45
2020 General $6,243 20
2019 General $11,740 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Evans
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Victor Evans were reported at $579. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Victor Evans Child & Adolescent Psychiatry median Middle half National median
2019 $11,740 $129 $42–$419 $163
2020 $6,243 $81 $28–$226 $114
2021 $3,392 $115 $31–$326 $132
2022 $619 $124 $40–$382 $149
2023 $2,849 $130 $45–$420 $160
2024 $436 $141 $42–$490 $164
2025 $579 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $15,060 64 payments
  2. Tris Pharma Inc $6,455 62 payments
  3. Corium, Inc. $2,525 25 payments
  4. Supernus Pharmaceuticals, Inc. $645 31 payments
  5. Janssen Pharmaceuticals, Inc $361 21 payments
  6. Ironshore Pharmaceuticals Inc. $176 11 payments
  7. Arbor Pharmaceuticals, Inc. $129 25 payments
  8. Neos Therapeutics, LP $108 8 payments
  9. Adlon Therapeutics L.P. $92 6 payments
  10. Vertical Pharmaceuticals, LLC $66 4 payments
  11. Other $243 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,076 9 payments
  2. Food and Beverage $4,781 239 payments
  3. Honoraria $4,000 3 payments
  4. Travel and Lodging $2,621 17 payments
  5. Consulting Fee $360 1 payment
  6. Gift $20 1 payment
  7. Education $0 1 payment
Products named General payments · program years 2019–2025
  1. VYVANSE Neuroscience $8,949 19 payments
  2. Dyanavel XR Adhd $5,774 26 payments
  3. Vyvanse Central Nervous System (CNS) $5,559 11 payments
  4. Azstarys $2,525 25 payments
  5. TRINTELLIX $596 37 payments
  6. Dyanavel XR Adhd $576 28 payments
  7. QELBREE Psychology $375 18 payments
  8. INVEGA SUSTENNA $314 18 payments
  9. Qelbree Viloxazine Hydrochloride $271 13 payments
  10. ADHANSIA XR $92 6 payments
  11. Other $998 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

143

Median for Neuropsychiatry: 88

Drug cost

$23,316

Median for Neuropsychiatry: $2,689

Branded share of claims

72.7%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 33 $18,586
Lisdexamfetamine Dimesylate Generic 11 $2,986
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 30 $747
Bupropion Xl Bupropion Hcl Brand 20 $512
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 21 $333
Alprazolam Generic 17 $99
Clonazepam Generic 11 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $134
$134 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $84
$84 33 —
Dyanavel XR
  • Tris Pharma Inc $63
$63 — —
Azstarys
  • Corium, Inc. $59
$59 — —
Xelstrym
  • Noven Therapeutics, LLC $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record